ATE464049T1 - Pharmazeutische kombinationen von hydrocodon und naltrexon - Google Patents

Pharmazeutische kombinationen von hydrocodon und naltrexon

Info

Publication number: ATE464049T1
Authority: AT; Austria
Prior art keywords: naltrexone; hydrocodone; pharmaceutical combinations; pharmaceutically acceptable; acceptable salt
Prior art date: 2003-09-25

Application number

AT04788669T

Other languages

English (en)

Inventor

Benjamin Oshlack

Curtis Wright

Chris Breder

Original Assignee

Euro Celtique Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-25

Filing date

2004-09-09

Publication date

2010-04-15

2004-09-09 Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa

2010-04-15 Application granted granted Critical

2010-04-15 Publication of ATE464049T1 publication Critical patent/ATE464049T1/de

Links

XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 title abstract 2
LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 title abstract 2
229960000240 hydrocodone Drugs 0.000 title abstract 2
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 title abstract 2
DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 title abstract 2
229960003086 naltrexone Drugs 0.000 title abstract 2
LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 title abstract 2
150000003839 salts Chemical class 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Emergency Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT04788669T 2003-09-25 2004-09-09 Pharmazeutische kombinationen von hydrocodon und naltrexon ATE464049T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US50622203P	2003-09-25	2003-09-25
PCT/US2004/029521 WO2005032555A2 (en)	2003-09-25	2004-09-09	Pharmaceutical combinations of hydrocodone and naltrexone

Publications (1)

Publication Number	Publication Date
ATE464049T1 true ATE464049T1 (de)	2010-04-15

Family

ID=34421533

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04788669T ATE464049T1 (de)	2003-09-25	2004-09-09	Pharmazeutische kombinationen von hydrocodon und naltrexon

Country Status (13)

Country	Link
US (2)	US20060194826A1 (de)
JP (1)	JP4758897B2 (de)
AT (1)	ATE464049T1 (de)
AU (2)	AU2004277898B2 (de)
CA (1)	CA2539027C (de)
DE (1)	DE602004026604D1 (de)
DK (1)	DK1663229T3 (de)
ES (1)	ES2344350T3 (de)
HR (1)	HRP20100368T1 (de)
IL (1)	IL174537A (de)
MX (1)	MXPA06003392A (de)
PT (1)	PT1663229E (de)
WO (1)	WO2005032555A2 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU229705B1 (en)	2000-02-08	2014-05-28	Euro Celtique Sa	Tamper-resistant oral opioid agonist formulations
SI1416842T1 (sl)	2001-07-18	2009-06-30	Euro Celtique Sa	Farmacevtske kombinacije oksikodona in naloksona
US7776314B2 (en)	2002-06-17	2010-08-17	Grunenthal Gmbh	Abuse-proofed dosage system
MY135852A (en)	2003-04-21	2008-07-31	Euro Celtique Sa	Pharmaceutical products
HUE034290T2 (en)	2003-04-29	2018-02-28	Orexigen Therapeutics Inc	Preparations containing opioid antagonist and bupropion to affect weight loss
DE10361596A1 (de)	2003-12-24	2005-09-29	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102005005446A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de)	2003-08-06	2005-03-24	Grünenthal GmbH	Gegen Missbrauch gesicherte Darreichungsform
US20070048228A1 (en)	2003-08-06	2007-03-01	Elisabeth Arkenau-Maric	Abuse-proofed dosage form
DE102004032049A1 (de)	2004-07-01	2006-01-19	Grünenthal GmbH	Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de)	2005-02-04	2006-08-10	Grünenthal GmbH	Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
CA2630624C (en)	2005-11-22	2013-08-06	Orexigen Therapeutics, Inc.	Compositions and methods for increasing insulin sensitivity
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
ES2749800T3 (es) *	2006-06-05	2020-03-23	Nalpropion Pharmaceuticals Llc	Formulación de liberación sostenida de naltrexona
KR20170077291A (ko)	2006-11-09	2017-07-05	오렉시젠 세러퓨틱스 인크.	단위 용량 팩키지
EP2065038A1 (de)	2007-11-30	2009-06-03	Pharnext	Neue therapeutische Ansätze zur Behandlung der Charcot-Marie-Tooth Krankheit
US8486448B2 (en)	2007-12-17	2013-07-16	Paladin Labs Inc.	Misuse preventative, controlled release formulation
CA2713128C (en)	2008-01-25	2016-04-05	Gruenenthal Gmbh	Pharmaceutical dosage form
US9226907B2 (en)	2008-02-01	2016-01-05	Abbvie Inc.	Extended release hydrocodone acetaminophen and related methods and uses thereof
AU2009243681B2 (en)	2008-05-09	2013-12-19	Grunenthal Gmbh	Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
JP2011521973A (ja)	2008-05-30	2011-07-28	オレキシジェン・セラピューティクス・インコーポレーテッド	内臓脂肪の状態を処置するための方法
BRPI0913724B8 (pt) *	2008-09-18	2021-05-25	Purdue Pharma Lp	formas farmacêuticas de liberação prolongada compreendendo naltrexona e poli (e-caprolactona) e seu preparo
ES2509497T3 (es)	2008-12-16	2014-10-17	Paladin Labs Inc.	Formulación de liberación controlada para evitar un uso indebido
WO2010141505A1 (en) *	2009-06-01	2010-12-09	Protect Pharmaceutical Corporation	Abuse-resistant delivery systems
EP2263665A1 (de)	2009-06-02	2010-12-22	Pharnext	Neue Zusammensetzungen zur Behandlung von CMT und verwandten Erkrankungen
US9393241B2 (en)	2009-06-02	2016-07-19	Pharnext	Compositions for treating CMT and related disorders
CN102639118B (zh)	2009-07-22	2015-07-29	格吕伦塔尔有限公司	氧化稳定的抗干扰剂型
KR101738369B1 (ko)	2009-07-22	2017-05-22	그뤼넨탈 게엠베하	핫 멜트 압출된 제어 방출 투여형
ES2762113T3 (es)	2010-01-11	2020-05-22	Nalpropion Pharmaceuticals Inc	Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
ES2606227T3 (es)	2010-02-03	2017-03-23	Grünenthal GmbH	Preparación de una composición farmacéutica en polvo mediante una extrusora
WO2011112956A1 (en) *	2010-03-12	2011-09-15	Government Of The Usa, As Represented By The Sec., Dept. Of Health And Human Services	Agonist/antagonist compositions and methods of use
TWI516286B (zh)	2010-09-02	2016-01-11	歌林達股份有限公司	含陰離子聚合物之抗破碎劑型
BR112013005194A2 (pt)	2010-09-02	2016-05-03	Gruenenthal Gmbh	forma de dosagem resistente à violação compreendendo sal inorgânico
BR112014001091A2 (pt)	2011-07-29	2017-02-14	Gruenenthal Gmbh	comprimido resistente à adulteração que fornece liberação imediata do fármaco
EA201400172A1 (ru)	2011-07-29	2014-06-30	Грюненталь Гмбх	Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства
MX356421B (es)	2012-02-28	2018-05-29	Gruenenthal Gmbh	Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
EP2838512B1 (de)	2012-04-18	2018-08-22	Grünenthal GmbH	Fälschungssichere und dose dumping sichere pharmazeutische darreichungsform
US10064945B2 (en)	2012-05-11	2018-09-04	Gruenenthal Gmbh	Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
LT3730132T (lt)	2012-06-06	2022-08-25	Nalpropion Pharmaceuticals Llc	Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde
US8987289B2 (en)	2012-12-14	2015-03-24	Trevi Therapeutics, Inc.	Methods for treating pruritus
US8637538B1 (en)	2012-12-14	2014-01-28	Trevi Therapeutics, Inc.	Methods for treatment of pruritis
US20140179727A1 (en)	2012-12-14	2014-06-26	Trevi Therapeutics, Inc.	Methods for treating pruritus
EP3003279A1 (de)	2013-05-29	2016-04-13	Grünenthal GmbH	Manipulationssichere darreichungsform mit einem oder mehreren partikeln
US9737490B2 (en)	2013-05-29	2017-08-22	Grünenthal GmbH	Tamper resistant dosage form with bimodal release profile
DK3003268T3 (en)	2013-06-05	2018-11-05	Pharnext	STABLE ORAL SOLUTIONS FOR COMBINED API
BR112016000194A8 (pt)	2013-07-12	2019-12-31	Gruenenthal Gmbh	forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
CA3042642A1 (en)	2013-08-12	2015-02-19	Pharmaceutical Manufacturing Research Services, Inc.	Extruded immediate release abuse deterrent pill
EP3073994A1 (de)	2013-11-26	2016-10-05	Grünenthal GmbH	Herstellung einer pulverförmigen pharmazeutischen zusammensetzung mittels kryogenen mahlens
US8969371B1 (en)	2013-12-06	2015-03-03	Orexigen Therapeutics, Inc.	Compositions and methods for weight loss in at risk patient populations
US10172797B2 (en)	2013-12-17	2019-01-08	Pharmaceutical Manufacturing Research Services, Inc.	Extruded extended release abuse deterrent pill
US9492444B2 (en)	2013-12-17	2016-11-15	Pharmaceutical Manufacturing Research Services, Inc.	Extruded extended release abuse deterrent pill
WO2015173195A1 (en)	2014-05-12	2015-11-19	Grünenthal GmbH	Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru)	2014-05-26	2017-05-31	Грюненталь Гмбх	Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
CA2955229C (en)	2014-07-17	2020-03-10	Pharmaceutical Manufacturing Research Services, Inc.	Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en)	2014-10-20	2017-05-04	Pharmaceutical Manufacturing Research Services, Inc.	Extended release abuse deterrent liquid fill dosage form
WO2016170097A1 (en)	2015-04-24	2016-10-27	Grünenthal GmbH	Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (ja)	2015-09-10	2018-09-13	グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング	乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
US10383870B2 (en)	2016-06-10	2019-08-20	Pharnext	Early treatment of CMT disease
IL318587A (en)	2018-07-23	2025-03-01	Trevi Therapeutics Inc	Treatment of chronic cough, shortness of breath and wheezing
IL294601A (en)	2020-01-10	2022-09-01	Trevi Therapeutics Inc	Methods of administration of nalbuphine

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4457933A (en) *	1980-01-24	1984-07-03	Bristol-Myers Company	Prevention of analgesic abuse
US4769372A (en)	1986-06-18	1988-09-06	The Rockefeller University	Method of treating patients suffering from chronic pain or chronic cough
US5215758A (en)	1991-09-11	1993-06-01	Euroceltique, S.A.	Controlled release matrix suppository for pharmaceuticals
US5472943A (en)	1992-09-21	1995-12-05	Albert Einstein College Of Medicine Of Yeshiva University,	Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
DE69709646T2 (de) *	1996-03-12	2002-08-14	Alza Corp., Palo Alto	Zusammensetzung und dosisform mit einem opioid-antagonisten
US6274591B1 (en) *	1997-11-03	2001-08-14	Joseph F. Foss	Use of methylnaltrexone and related compounds
JP2001526228A (ja)	1997-12-22	2001-12-18	ユーロ−セルティーク，エス．エイ．	オピオイド作動薬／拮抗薬の併用
CA2314896C (en)	1997-12-22	2005-09-13	Euro-Celtique, S.A.	A method of preventing abuse of opioid dosage forms
US6375957B1 (en) *	1997-12-22	2002-04-23	Euro-Celtique, S.A.	Opioid agonist/opioid antagonist/acetaminophen combinations
HU229705B1 (en) *	2000-02-08	2014-05-28	Euro Celtique Sa	Tamper-resistant oral opioid agonist formulations
SI1416842T1 (sl) *	2001-07-18	2009-06-30	Euro Celtique Sa	Farmacevtske kombinacije oksikodona in naloksona
ATE431738T1 (de) *	2001-08-06	2009-06-15	Euro Celtique Sa	Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
US7842307B2 (en) *	2001-08-06	2010-11-30	Purdue Pharma L.P.	Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US7332182B2 (en) *	2001-08-06	2008-02-19	Purdue Pharma L.P.	Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
AU2002324624A1 (en) *	2001-08-06	2003-02-24	Euro-Celtique S.A.	Sequestered antagonist formulations
KR20040098660A (ko) *	2002-03-14	2004-11-20	유로-셀티크 소시에떼 아노뉨	날트렉손 하이드로클로라이드 조성물
EP1492505B1 (de) *	2002-04-05	2015-06-03	Euro-Celtique S.A.	Pharmazeutische zubereitung enthaltend oxycodon und naloxon
US20030191147A1 (en) *	2002-04-09	2003-10-09	Barry Sherman	Opioid antagonist compositions and dosage forms
US20040192715A1 (en) *	2003-02-05	2004-09-30	Mark Chasin	Methods of administering opioid antagonists and compositions thereof
MY135852A (en) *	2003-04-21	2008-07-31	Euro Celtique Sa	Pharmaceutical products
US20080020028A1 (en) *	2003-08-20	2008-01-24	Euro-Celtique S.A.	Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
US20050245557A1 (en) *	2003-10-15	2005-11-03	Pain Therapeutics, Inc.	Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain

2004
- 2004-09-09 MX MXPA06003392A patent/MXPA06003392A/es active IP Right Grant
- 2004-09-09 US US10/562,494 patent/US20060194826A1/en not_active Abandoned
- 2004-09-09 AT AT04788669T patent/ATE464049T1/de active
- 2004-09-09 PT PT04788669T patent/PT1663229E/pt unknown
- 2004-09-09 DE DE602004026604T patent/DE602004026604D1/de not_active Expired - Lifetime
- 2004-09-09 WO PCT/US2004/029521 patent/WO2005032555A2/en not_active Ceased
- 2004-09-09 CA CA2539027A patent/CA2539027C/en not_active Expired - Fee Related
- 2004-09-09 HR HR20100368T patent/HRP20100368T1/hr unknown
- 2004-09-09 ES ES04788669T patent/ES2344350T3/es not_active Expired - Lifetime
- 2004-09-09 DK DK04788669.2T patent/DK1663229T3/da active
- 2004-09-09 AU AU2004277898A patent/AU2004277898B2/en not_active Ceased
- 2004-09-09 JP JP2006528039A patent/JP4758897B2/ja not_active Expired - Fee Related
2006
- 2006-03-23 IL IL174537A patent/IL174537A/en not_active IP Right Cessation
2009
- 2009-03-18 AU AU2009201097A patent/AU2009201097B2/en not_active Ceased
2014
- 2014-10-01 US US14/504,063 patent/US20150080423A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2009201097A8 (en)	2009-04-23
HK1091733A1 (en)	2007-01-26
CA2539027A1 (en)	2005-04-14
PT1663229E (pt)	2010-07-13
JP2007506738A (ja)	2007-03-22
US20060194826A1 (en)	2006-08-31
CA2539027C (en)	2010-02-23
ES2344350T3 (es)	2010-08-25
DK1663229T3 (da)	2010-08-09
MXPA06003392A (es)	2006-06-08
IL174537A0 (en)	2006-08-01
DE602004026604D1 (de)	2010-05-27
WO2005032555A2 (en)	2005-04-14
AU2004277898A1 (en)	2005-04-14
IL174537A (en)	2012-01-31
WO2005032555A3 (en)	2005-05-12
HRP20100368T1 (hr)	2010-08-31
JP4758897B2 (ja)	2011-08-31
AU2009201097B2 (en)	2011-03-31
US20150080423A1 (en)	2015-03-19
AU2004277898B2 (en)	2009-04-02
AU2009201097A1 (en)	2009-04-09

Publication	Publication Date	Title
ATE464049T1 (de)	2010-04-15	Pharmazeutische kombinationen von hydrocodon und naltrexon
ATE419039T1 (de)	2009-01-15	Pharmazeutische kombinationen von oxycodon und naloxon
EA200301165A1 (ru)	2004-06-24	Лекарственное средство на основе оксикодона
WO2005065646A3 (en)	2005-12-08	Novel drug compositions and dosage forms
DE60013630D1 (de)	2004-10-14	Arzneimittel zur behandlung von darmverstopfung und reizkolon
PT1585548T (pt)	2018-10-17	Composições e métodos de administração de agentes farmacológicos
WO2004005324A3 (en)	2004-03-25	Peptide composition for treatment of sexual dysfunction
BR0316948A (pt)	2005-10-18	Composto, formulação farmacêutica, e, uso de um composto
BRPI0410049A (pt)	2006-04-25	composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, uso de um composto, composição farmacêutica, e, kit farmacêutico
TR200101719T2 (tr)	2002-08-21	Erkeklerde organik ereksiyona bağlı işlev bozukluğunun tedavisi için ilaç imalatında apomorfin kullanımı
NO20062019L (no)	2006-07-06	P-glykoproteininhibitor, fremgangsmater for fremstilling av denne samt farmasoytiske preparater inneholdende den samme
AR034343A1 (es)	2004-02-18	Combinaciones farmaceuticas
WO2002088100A3 (de)	2003-05-30	Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
EA200800880A1 (ru)	2009-02-27	Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
EA200700901A1 (ru)	2007-10-26	Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
SE0102440D0 (sv)	2001-07-05	New compound
WO2005065648A3 (en)	2005-12-08	Novel drug compositions and dosage forms of topiramate
EP1849468A3 (de)	2007-11-07	Pharmazeutische Zusammensetzung enthaltend einen pde4 oder pde3/4 Inhibitor und eine Histaminrezeptorantagonisten
EP1784173A4 (de)	2009-07-01	Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat-derivaten
AU2003256157A1 (en)	2004-02-23	Oral dosage forms of water insoluble drugs and methods of making the same
YU87501A (sh)	2004-05-12	Farmaceutski kompleksi
HUP0301906A3 (en)	2006-03-28	Use of bicyclo[2.2.1]heptane derivatives for producing of pharmaceutical compositions having neuroprotectiv activity
CY1110207T1 (el)	2015-01-14	Φαρμακευτικοι συνδυασμοι υδροκοδωνης και ναλτρεξονης
AU2003281257A8 (en)	2004-01-23	A novel use of rapamycin and structural analogues thereof
AR030660A1 (es)	2003-08-27	Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12